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Hardy–Weinberg formulation also predicts that the allelic
frequencies will remain stable from generation to gene-
ration, provided that there is no mutation, no migration,
and no natural selection in a very large population with
random mating. If the evolutionary pressures are active and/
or when the mating is not random, we can observe a
significant deviation from the expected frequencies of the
genotypes.
I read the article of Lin et al.1 with great interest and I
would like to make a few comments about it. The authors
determined a genetic polymorphism in the promoter region
of heme oxygenase-1 gene and then investigated its associa-
tion with arteriovenous fistula failure in Chinese hemodia-
lysis patients in Taiwan. They also included 286 individuals
without renal disease as control group. A dinucleotide repeat
(GT) of different length was identified in the proximal
promoter region of the human heme oxygenase-1 gene. The
authors assigned those with GT repeats X30 as allele class L
(long) and those with GT repeatso30 as allele class S (short).
Based on Table 2 of the article of Lin et al.,1 61, 163, and 62
persons showed S/S, L/S, and L/L genotypes, respectively.
There is significant deviation from Hardy–Weinberg equili-
brium (w2¼ 5.595, df¼ 1, P¼ 0.025).
Unfortunately, the authors did not mention why their
control group is not on Hardy–Weinberg equilibrium. Is
there any problem for selecting the control subjects? The
observed frequency for the heterozygote genotype was 56.9%,
whereas the expected frequency of the genotype was 49.9%.
On the other hand, both homozygote genotypes were
decreased in the control group compared to expected values.
Therefore, it is possible that the control subjects were chosen
from at least two different gene pools (or different
populations). What we can say about the patients? If they
belong to different gene pools, is there any difference(s)
between these populations for the prevalence of coronary
artery disease, cardiovascular disease, and arteriovenous
fistula failure? Finally, it seems that the reliability of the
results of Lin et al.1 dramatically decreased, and therefore
their findings must be interpreted with caution.
1. Lin CC, Yang WC, Lin SJ et al. Length polymorphism in heme oxygenase-1
is associated with arteriovenous fistula patency in hemodialysis patients.
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equilibrium and control subjects’
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The authors thank Saadat1 for raising an essential issue
regarding Hardy–Weinberg equilibrium in carrying out
case–control association studies. In our paper, the main
theme was to analyze the association between HO-1 repeat
polymorphisms and arteriovenous fistula patency in
patients underwent hemodialysis. Thus, the comparisons
were mostly based on differences of genotypes between the
two case groups, that is those with and without fistula
failure. Hardy–Weinberg equilibrium was not violated in
the two case groups; therefore, the tests that we performed
were valid and so did the conclusions.
We were aware of the deviation of Hardy–Weinberg
equilibrium for the control group; therefore, the test of
association between Huntington’s disease patients and
controls was carried out by Armitage’s trend test (a valid
test even in Hardy–Weinberg disequilibrium), which was
not mentioned in our paper. To clarify further, we now add
‘using Armigates’ trend test’ in the footnote of Table 2 after
‘* signifies the P-value for the comparison between
controls and Huntington’s disease patients’.
Regarding the variation among populations, we did
genotype three informative SNP markers for Chinese sub-
populations, rs727258, rs108996795, and rs10506294, to
rule out population stratification.2 The results supported
no difference between control and the two case groups
(data not shown).
1. Saadat M. Hardy–Weinberg equilibrium and control subjects. Kidney Int
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Ultrasonography and graft
patency
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To the Editor: Robbin et al.1 have recently published an
interesting randomized study assessing the impact of
ultrasound surveillance on arteriovenous graft outcomes.
This study failed to prolong graft patency by means of
screening ultrasonography. This finding is in contradiction to
our randomized study,2 published a couple of months earlier,
where adding of ultrasound to clinical monitoring was
associated with significantly longer graft patency. A post hoc
analysis by Dossabhoy et al.3 supported our data.
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There are several differences in the study design that could
theoretically explain contradictory results.
Robbin et al.1 included subjects later after surgery – the
mean graft age was 9 months at inclusion, while we performed
inclusion and first ultrasound examination within 4 weeks
after access creation. We could hypothesize that high-risk
grafts, which thrombose within first year after access creation,
were therefore not included into Robbin’s study. Such patients
probably profit from ultrasound surveillance most.
Another difference is that although Robbin et al.1
performed a single-center study, our patients were hemodia-
lyzed in 25 centers. Although all dialysis centers in our study
made every effort to follow K/Dialysis Outcome Quality
Initiative guidelines, their experience could vary. Access flow
was monitored in less than 50% of patients in our study.
These factors could increase the profit of ultrasound
surveillance in our study. We think that multi-center study
reflects better routine care, which is probably less perfect than
in highly specialized hemodialysis units of university
hospitals. On the contrary, in the light of Dossabhoy’s study,
higher use of access flow monitoring would probably not
change dramatically our results.
1. Robbin ML, Oser RF, Lee JY et al. Randomized comparison of ultrasound
surveillance and clinical monitoring on arteriovenous graft outcomes.
Kidney Int 2006; 69: 730–735.
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We thank Dr Malik1 for his interest. Our average graft age
at enrollment was 8.877.3 months,2 whereas Malik’s
patients were enrolled by 1 month.3 Malik’s study showed
a significant difference between control and ultrasound
group by 6 months of graft age. We potentially did not
enroll some problematic grafts that failed by 6–9 months.
However, 27% of our grafts had a prior thrombectomy, and
33% had a prior percutaneous transluminal angioplasty.
Furthermore, our subgroup analysis of 57 ‘virgin’ grafts
(45%) showed no significant difference in time to graft
failure or thrombosis-free survival between the ultrasound
and control group. Thus, the difference between the study
results is unlikely to be owing to graft age at enrollment.
Additionally, even after 9 months, Malik’s data show a
continued steep decline in the access patency of control
group grafts, not demonstrated in our data.
Our data represent five University of Alabama centers
with fairly uniform graft assessments. Practice patterns may
differ more widely between the 25 centers in Malik’s study.
Access flow was monitored in about 50% of the control
patients in Malik’s study. We performed comparable
routine graft clinical monitoring, but did not perform
access flow, dynamic pressure, or recirculation measure-
ments. The study differences may be due, in part, to our
more frequent routine clinical monitoring. Angioplasty
versus thrombectomy frequencies for Malik’s groups
would be useful in this assessment.
Ultrasound can detect graft stenoses that are not
clinically significant.4 However, no benefit of pre-emptive
angioplasty in clinically asymptomatic stenoses was
demonstrated in our study.
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ACE inhibitor use and the
long-term risk of renal failure
in diabetes
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To the Editor: We read with great interest the recent paper by
Suissa et al.1 The authors found that the use of angiotensin-
converting enzyme inhibitors (ACEI) by patients with
diabetes was not associated with long-term decreased risk
of renal failure. Their findings suggested instead a higher risk
of renal failure in those who took ACEI, even after having
adjusted for other risk factors.
In our previous publication,2 where we reported that
ACEI/angiotensin II receptor antagonist (ATRA) therapy
decreases proteinuria by improving glomerular permselec-
tivity in IgA nephritis, we found ATRA to be superior. Our
data showed that majority of the non-responders were on
ACEI compared to the responders who were on ATRA
(w2¼ 6.3, Po0.02; Table 1a), suggesting that ATRA is more
effective in decreasing proteinuria. In this respect, we are not
surprised by the data of Suissa et al.,1 who showed that ACEI
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